bioRxiv · 10.1101/2021.12.02.470987
Single immunization with recombinant ACAM2000 vaccinia viruses expressing the spike and the nucleocapsid proteins protect hamsters against SARS-CoV-2 caused clinical disease
Abstract
Increasing cases of SARS-CoV-2 breakthrough infections from immunization with predominantly spike protein based COVID-19 vaccines highlight the need for alternative vaccines using different platforms and/or antigens. In this study, we expressed SARS-CoV-2 spike and nucleocapsid proteins in a novel vaccinia virus ACAM2000 platform (rACAM2000). Following a single intramuscular immunization, the rACAM2000 co-expressing the spike and nucleocapsid proteins induced significantly improved protection against SARS-CoV-2 challenge in comparison to rACAM2000 expressing the individual proteins in a hamster model, as shown by reduced weight loss and quicker recovery time. The protection was associated with reduced viral loads, increased neutralizing antibody titre and reduced neutrophil-to-lymphocyte ratio. Thus, our study demonstrates that the rACAM2000 expressing a combination of the spike and nucleocapsid antigens is a promising COVID-19 vaccine candidate and further studies will investigate if the rACAM2000 vaccine candidate can induce a long lasting immunity against infection of SARS-CoV-2 variants of concern.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Cao, J., Deschambault, Y., Lynch, J., Warner, B., Tierney, K., Huynh, D., Vendramelli, R., Tailor, N., Booth, S., Sajesh, B., Frost, K., LeBlanc, K., Layne, C., Lin, L., Beniac, D., Carpenter, M., Safronetz, D., Li, X., Kobasa, D.. 2021-12-03. Single immunization with recombinant ACAM2000 vaccinia viruses expressing the spike and the nucleocapsid proteins protect hamsters against SARS-CoV-2 caused clinical disease. https://doi.org/10.1101/2021.12.02.470987
Cite the original work for its findings. Save a collection to share your selection of sources.